دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
برای ارتباط با ما می توانید از طریق شماره موبایل زیر از طریق تماس و پیامک با ما در ارتباط باشید
در صورت عدم پاسخ گویی از طریق پیامک با پشتیبان در ارتباط باشید
برای کاربرانی که ثبت نام کرده اند
درصورت عدم همخوانی توضیحات با کتاب
از ساعت 7 صبح تا 10 شب
ویرایش:
نویسندگان: Markus Moehler (editor). Friedrich Foerster (editor)
سری:
ISBN (شابک) : 3031399439, 9783031399435
ناشر: Springer
سال نشر: 2024
تعداد صفحات: 304
[291]
زبان: English
فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود)
حجم فایل: 9 Mb
در صورت تبدیل فایل کتاب Immune Strategies for Gastrointestinal Cancer (Cancer Immunotherapy, 2) به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب استراتژی های ایمنی برای سرطان دستگاه گوارش (ایمنی درمانی سرطان، 2) نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
این کتاب مروری بر شواهد موجود پیرامون ایمونوتراپی در سرطان های دستگاه گوارش ارائه می دهد و جایگاه آینده آن را در عمل بالینی مورد بحث قرار می دهد. ایمونوتراپی موفقیتهای درمانی شگفتانگیزی را در انواع مختلف سرطان کسب کرده است و به طور فزایندهای در عملکرد بالینی روزانه مرتبط میشود. در حال حاضر، کلاس غالب داروهای ایمونوتراپی، به اصطلاح مهارکنندههای بازرسی هستند که ترمزهای فیزیولوژیکی سیستم ایمنی را از بین میبرند و پاسخ ایمنی ضد سرطانی مؤثرتری را ممکن میسازند. بدخیمی های دستگاه گوارش، که اکثر موارد سرطان در سراسر جهان را تشکیل می دهند، یکی از دلایل اصلی عوارض و مرگ و میر هستند و نیاز فوری به درمان های موثرتر را ایجاد می کنند. تعداد زیادی از کارآزماییهای بالینی کارایی ایمونوتراپی سرطان را در بدخیمیهای دستگاه گوارش ارزیابی کردهاند و پتانسیل آن را در زیر مجموعههای خاصی از بیماران نشان دادهاند. این کتاب برای خوانندگان گسترده ای از جمله انکولوژیست ها، متخصصان مراقبت های بهداشتی به طور کلی و دانشمندان زیست پزشکی جذاب خواهد بود.
This book provides an overview of the available evidence surrounding immunotherapy in gastrointestinal cancers, and discusses its future place in clinical practice. Immunotherapy has celebrated some astonishing therapeutic successes in a variety of cancer types and is becoming increasingly relevant in daily clinical practice. Currently, the predominant class of immunotherapeutic drugs is the so-called checkpoint inhibitors, which disengage the physiological brakes on the immune system, enabling a more effective anti-cancer immune response. Malignancies of the gastrointestinal tract, which account for the majority of cancer cases worldwide, are a major cause of morbidity and mortality, creating an urgent need for more effective therapies. A large number of clinical trials have evaluated the efficacy of cancer immunotherapy in gastrointestinal malignancies and demonstrated its potential in certain subsets of patients. This book will appeal to a wide readership, including oncologists, health care professionals in general and biomedical scientists.
Immunotherapy in GI Cancers: Introduction Contents Part I: Role of the Tumor Microenvironment An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies 1 An Overview of Gastrointestinal Malignancies 2 Key Players in the Tumor Microenvironment 3 Cancer and Stromal Cell Cross-Talk: Role of Epithelial to Mesenchymal Transition 4 Tumor Microenvironment: The Role of Tumor-Associated Macrophages (TAM) 5 New Interest in Cancer Immunology: Myeloid-Derived Suppressor Cells (MDSCs) 6 Adaptive Immunity in Cancer Immunotherapy 7 Natural Killer (NK) Cells as a Novel Frontier in Cancer Immunotherapy 8 Dendritic Cells (DCs) Link the Innate and Adaptive Immune System 9 Targeting the Tumor Microenvironment to Enhance Clinical Immunotherapy 10 The Tumor Microenvironment and Response to Immunotherapy in GI Malignancies 11 Concluding Remarks References Part II: Esophagus Approach to Immunotherapy in Oesophageal Cancer 1 Background 2 Oesophageal Squamous Cell Cancer 2.1 Single-Agent Anti-PD-1 Antibodies 2.2 Anti-PD-1 Antibodies in Combination with Other Systemic Therapies 2.3 Early Disease 3 Oesophageal Adenocarcinoma 3.1 Single-Agent Anti-PD-1 Antibodies 3.2 Anti-PD-1 Antibodies in Combination with Other Systemic Antibodies 3.3 Early Disease 4 Concluding Remarks References Perspective on the Immunotherapy of Esophageal Cancer 1 Introduction 2 The Suppressed Immune Microenvironment of ESCC and EAC and Response to Immunotherapy 3 Stromal Derived Immune Modulation 4 Checkpoint Inhibition and Conventional Anti-Cancer Treatments in Esophagogastric Cancer: New Roads Ahead? 5 Immunotherapy Beyond Checkpoint Inhibitors 6 Microbiome 7 Concluding Remarks References Part III: Stomach Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies 1 Introduction 2 Role of Targeted Therapies 3 Rational for Immunotherapy 4 Biomarkers of Immunotherapy 5 Immunotherapy for MSI Locally AGC 6 Immunotherapy for HER2+ GC 7 Immune Strategies for Resectable Non-MSI Non-HER2+ GC 8 Adjuvant Immunotherapy in Oesophageal-Gastric Cancer References Stomach: The Standard of Care ± HER2 1 Introduction 2 Molecular Subtypes in Gastric Cancer 3 Chemotherapy for Advanced Gastric Cancer 4 Role of Angiogenesis Blockade in Metastatic Gastric Cancer 5 Targeting HER2 6 Immunotherapy for Gastric Cancer 7 Conclusion References Perspective on the Immunotherapy of Gastric Cancer 1 Biomarkers of ICIs in Gastric Cancer 1.1 PD-L1 CPS 1.2 Microsatellite Instability-High 1.3 Tumor Mutation Burden 1.4 Epstein–Barr Virus (EBV) 1.5 Others 1.5.1 Hyperprogressive Disease 1.5.2 Gene Expression Signatures 2 Combined Immunotherapy 2.1 ICIs Plus Chemotherapy 2.2 ICI Doublet: Anti-PD-1/PD-L1 Antibody Plus Anti-CTLA4 Antibody 2.3 Anti-HER2 Antibody Plus Immune Checkpoint Inhibitors 2.4 ICIs and VEGF Inhibitors 2.5 ICIs and Local Therapies 2.6 ICIs and Other Targeted Agents 2.6.1 ICI and PARP Inhibitor 2.6.2 ICI and DKN-01 2.7 Others (CAR-T and BiTEs) 3 Conclusion References Part IV: Colon Immunotherapy in dMMR/MSI-H Colon Cancer 1 Introduction 2 Evidence for Immunotherapy in dMMR/MSI-H CRC 2.1 Monotherapy with PD-1 Inhibitors 2.2 Combination of PD-1 and CTLA-4 Inhibitors 2.3 Combination of PD-L1 Inhibitor with Anti-angiogenic VEGF-Antibody 2.3.1 Ongoing Clinical Trials 3 Conclusions and Perspective References Immunotherapy in the Treatment of Advanced Colorectal Cancer 1 Introduction 2 Role of the Immune System in Colorectal Cancer 3 Strategies to Overcome ICI Resistance in pMMR/MSS Colorectal Cancer 3.1 BRAF/MAPK 3.2 VEGF Inhibitors 3.3 EGFR Inhibitors 3.4 MEK Inhibitors 3.5 POLE Mutations 3.6 IDO Inhibitors 3.7 Carcinoembryonic Antigen T-Cell Bispecific Protein 3.8 Toll-Like Receptor Agonists 3.9 Radiation Therapy 3.10 Costimulatory Receptor Agonists 4 Conclusion and Future Direction References Immunotherapy of Rectal Cancer 1 Introduction 2 Biology of Rectal Cancer 3 Completed Clinical Trials of Immunotherapy for Rectal Cancer 4 Ongoing Clinical Trials of Immunotherapy for Rectal Cancer 5 Conclusion References Perspective on Immunotherapy of Colon Cancer: Challenges for the Future References Part V: HCC Immune Strategies for Gastrointestinal Cancer: HCC 1 Introduction 2 Hepatic Immunobiology 3 Implications for HCC Classification and Treatment 4 Immunotherapy and HCC 4.1 Immune Checkpoint Blockade as Monotherapy 4.2 Immunotherapy-Based Combinations 4.2.1 Anti-VEGF plus Checkpoint Inhibitors Atezolizumab and Bevacizumab Combination 4.2.2 TKI and Checkpoint Inhibitor Pembrolizumab and Lenvatinib Ipilimumab and Nivolumab with Cabozantinib Pembrolizumab and Regorafenib Atezolizumab and Lenvatinib or Sorafenib 4.2.3 Combinations of Checkpoint Inhibitors Durvalumab and Tremelimumab Ipilimumab and Nivolumab 5 Locoregional Therapies and Immune System 6 Conclusion References Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective References Part VI: Biliary Tract Immunotherapy of Biliary Tract Cancer 1 Biliary Tract Cancer 2 Microenvironment and Immune Landscape in Biliary Tract Cancer 2.1 Cell Populations of the Innate Immune Response 2.2 Components of the Adaptive Immune Response 3 Molecular Subgroups of Biliary Tract Carcinoma in the Context of Immunotherapy 3.1 Targetable Molecular Alterations in Biliary Tract Carcinoma 3.2 FGFR2 Alterations 3.3 IDH1/IDH2 Mutations 3.4 Homologous Recombination Deficiency (HRD) 3.5 Mismatch Repair Deficiency (dMMR/MSI-H) 3.6 Other Targetable Molecular Subgroups of BTC 4 Immunotherapy for BTCs: Reported Clinical Outcomes 4.1 Anti-PD1/PD-L1 Immune Checkpoint Inhibitor Monotherapy 4.2 Anti-PD1/PD-L1 Plus Anti-CTLA-4 Combination Regimens 4.3 Immune Checkpoint Inhibitors in Combination with Chemotherapy 4.4 Anti-PD1/PD-L1 Immune Checkpoint Inhibitors in Combination with Small-Molecule Inhibitors 4.5 Novel Immunotherapeutic Agents Evaluated for BTCs 4.6 T Cell Therapies, Tumor Vaccines, and Oncolytic Viruses 5 Summary and Outlook References Perspective on Immunotherapy Use in Biliary Tract Cancer 1 Introduction 2 Monotherapy 3 Strategies for Overcoming Primary resistance 4 Combined PD-1 and CTLA-4 Inhibition 5 Chemotherapy in Combination with ICIs 6 Targeted Treatment in Combination with ICIs 7 GM-CSF in Combination with ICIs 8 Bintrafusp alfa 9 Localised Therapies in Combination with ICIs 10 Microsatellite Instability-High Tumours 11 Expert Opinion References Part VII: Pancreas Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective 1 Background 2 Immune Checkpoint Blockade (ICB) 2.1 Combined Chemo-Immunotherapy Approaches 2.2 CD40 Agonism 2.3 Immune Checkpoint Blockade and DNA Damage Response 2.4 Purinergic Signaling and Immunotherapy 3 Adoptive Cell Therapy 4 Therapeutic Vaccines 4.1 Cancer Vaccines and a Renewed Approach to Target KRAS 5 Targeting the Tumor Microenvironment 5.1 Targeting Tumor-Adjacent Immunosuppressive Cells 5.2 Targeting Stromal Elements 6 Autophagy Inhibition 7 Future Perspectives References Perspective on the Immunotherapy of Pancreatic Cancer 1 Introduction 2 Cancer Vaccines 3 Checkpoint Inhibitors 4 Inhibition of Suppressive Myeloid Cells 5 Overcoming the Suppressive Tumor Microenvironment 6 T Cell Cellular Therapy 7 Conclusions and Future Directions References Part VIII: Biomarkers for Immunotherapy in Gastrointestinal Cancers Biomarkers for Immunotherapy in Gastrointestinal Cancers 1 Introduction 2 Main Biomarkers for Immunotherapy in GI Cancers 2.1 Microsatellite Instability/Mismatch Repair Deficiency 2.2 Tumor Mutational Burden 2.3 PD-L1 Status 3 Colorectal Cancer 3.1 Microsatellite Instability/Mismatch Repair Deficiency 3.2 Tumor Mutational Burden 3.3 POLE and POLD1 Mutations 3.4 PD-L1 Status 3.5 Tumor-Infiltrating Lymphocytes and Immunoscore 4 Gastric Cancer 4.1 PD-L1 Status 4.2 Microsatellite Instability/Mismatch Repair Deficiency 4.3 Epstein–Barr Virus Status 4.4 Tumor Mutational Burden 4.5 Gene Expression Signatures 4.6 Neutrophil-to-Lymphocyte Ratio 5 Other GI Cancers 5.1 Esophageal Carcinoma 5.2 Anal Cancer 5.3 Hepatocellular Carcinoma 5.4 Pancreatic Adenocarcinoma 6 Conclusion References